DIADIA0.82%
SPYSPY0.83%
QQQQQQ1.30%
Trending
Top trending tickerSMCISMCI5.57%
ORCLORCL6.84%
WULFWULF2.33%
GLDGLD0.27%
SMCXSMCX10.56%
TETE6.86%
DJTDJT1.41%
SPYSPY0.83%
ARDXARDX3.03%
SQQQSQQQ3.87%
Top trending tickerSMCISMCI5.57%
ORCLORCL6.84%
WULFWULF2.33%
GLDGLD0.27%
SMCXSMCX10.56%
TETE6.86%
DJTDJT1.41%
SPYSPY0.83%
ARDXARDX3.03%
SQQQSQQQ3.87%
homeSymbolRDHLnews
RDHL logo

RDHLRedHill Biopharma Ltd.

$0.791
$0.089
(10.11%)
Pre-Market
Updated: 04:59 AM EDT·Prev Close $0.88
Mkt Cap$4.57M
Vol7,465.00

Feed

News

Sentiment

Fundamentals

Info

News
all
press releases
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation PR Newswire RALEIGH, N.C. and...
PR Newswire
News Placeholder
More News
News Placeholder
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo PR Newswire RALEIGH, N.C. and TEL-AVIV, Israel, June 8, 2026 RALEIGH, N.C.and TEL-AVIV, Israel, June 8...
PR Newswire
News Placeholder
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense...
PR Newswire
News Placeholder
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease RedHill's RHB-204 Demonstrates Comparable MAP Killing...
PR Newswire
News Placeholder
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights PR Newswire TEL AVIV...
PR Newswire
News Placeholder
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity...
PR Newswire
News Placeholder
H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) DelveInsight
H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight H. pylori Infections Market in the 6MM to Observe...
PR Newswire
News Placeholder
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) DelveInsight
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight Biliary Tract Cancer Market is Predicted to Exhibit...
PR Newswire
News Placeholder
Joint U.S. Commercialization of RedHill's Talicia Commences
Joint U.S. Commercialization of RedHill's Talicia Commences Joint U.S. Commercialization of RedHill's Talicia Commences PR Newswire RALEIGH, N.C. and TEL-AVIV, Israel, Feb. 25, 2026 The full sales...
PR Newswire
News Placeholder
What's Going On With Redhill Biopharma Stock On Tuesday?
RedHill Biopharma shares fell after a sharp rally as investors took profits, following updates on its GI drug aimed at easing GLP-1 treatment side effects and potential FDA approval paths.read more...
Benzinga
<
1
2
...
>

Advertisement|Remove ads.

Advertisement|Remove ads.